Daniel P. Rothschild
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel P. Rothschild has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
James A Goldstein
Department of Cardiovascular Medicine, Beaumont Health, Royal Oak, MI, USA
2 shared publicationsJames A. Goldstein
Department of Cardiovascular Medicine, Diseases, Beaumont Health, Royal Oak, Michigan
2 shared publications- Michael W. Rich
Washington University School of Medicine, St Louis, MO, USA
2 shared publications Amr E. Abbas
Department of Cardiovascular Medicine, Beaumont Health, 3601 West 13 Mile Road, Royal Oak, MI, 48073, USA
1 shared publicationAmy Mertens
William Beaumont Health System, Royal Oak, MI, USA
1 shared publicationDavid Preston
University of Kentucky, Lexington, KY; Veterans Affairs Medical Center, Lexington, KY
1 shared publication
Latest Publications
- 27 March 2019
- Published by SAGE Publications in Vascular Medicine
- Vol. 24 (3) , 234-240
Ultrasound-accelerated thrombolysis (USAT) versus standard catheter-directed thrombolysis (CDT) for treatment of pulmonary embolism: A retrospective analysis
Ultrasound-accelerated thrombolysis (USAT) is advocated in pulmonary embolism (PE) based on the hypothesis that adjunctive ultrasound provides superior clinical efficacy compared to standard catheter-directed thrombolysis (CDT). This retrospective study was designed to compare outcomes between the two modalities. We analyzed patients with computed tomography-diagnosed PE at our institution treated with either USAT or standard CDT. Efficacy parameters assessed included invasive pulmonary artery systolic pressure (PASP; pre- and 24 hours post-treatment), non-invasive right-to-left ventricle (RV/LV) ratio (pre- and post-treatment), and general clinical outcomes (length-of-stay, significant bleeding, and mortality). We analyzed 98 cases (62 USAT and 36 CDT), in whom massive PE was diagnosed in 7%, intermediate/high risk in 81%, and intermediate/low risk in 12%. Overall, 92% had bilateral clot and 40% saddle embolus. At 24 hours, PASP decreased similarly in both groups (CDT Δ14.7 mmHg, USAT Δ10.8 mmHg; p = 0.14). Post-treatment, CDT showed similar improvement in the RV/LV ratio (CDT Δ0.58 vs USAT Δ0.45; p = 0.07), despite the baseline ratio being greater in the CDT group, indicating more severe RV strain (1.56 ± 0.36 vs 1.40 ± 0.29; p = 0.01). Intensive care unit and hospital length-of-stays were similar in both groups. A trend toward lesser significant bleeding rates in the CDT group (8.3% vs 12.9%, p = 0.74) as well as improved survival-to-discharge (97.2% vs 91.9%, p = 0.66) was observed. Compared to USAT, standard CDT achieves similar beneficial effects on hemodynamics, RV/LV ratios, and clinical outcomes. These observations suggest that salutary clinical results may be achieved without the need for very expensive devices.
- 27 March 2019
- Published by SAGE Publications in Vascular Medicine
- Vol. 24 (3) , 234-240
Ultrasound-accelerated thrombolysis (USAT) versus standard catheter-directed thrombolysis (CDT) for treatment of pulmonary embolism: A retrospective analysis
Ultrasound-accelerated thrombolysis (USAT) is advocated in pulmonary embolism (PE) based on the hypothesis that adjunctive ultrasound provides superior clinical efficacy compared to standard catheter-directed thrombolysis (CDT). This retrospective study was designed to compare outcomes between the two modalities. We analyzed patients with computed tomography-diagnosed PE at our institution treated with either USAT or standard CDT. Efficacy parameters assessed included invasive pulmonary artery systolic pressure (PASP; pre- and 24 hours post-treatment), non-invasive right-to-left ventricle (RV/LV) ratio (pre- and post-treatment), and general clinical outcomes (length-of-stay, significant bleeding, and mortality). We analyzed 98 cases (62 USAT and 36 CDT), in whom massive PE was diagnosed in 7%, intermediate/high risk in 81%, and intermediate/low risk in 12%. Overall, 92% had bilateral clot and 40% saddle embolus. At 24 hours, PASP decreased similarly in both groups (CDT Δ14.7 mmHg, USAT Δ10.8 mmHg; p = 0.14). Post-treatment, CDT showed similar improvement in the RV/LV ratio (CDT Δ0.58 vs USAT Δ0.45; p = 0.07), despite the baseline ratio being greater in the CDT group, indicating more severe RV strain (1.56 ± 0.36 vs 1.40 ± 0.29; p = 0.01). Intensive care unit and hospital length-of-stays were similar in both groups. A trend toward lesser significant bleeding rates in the CDT group (8.3% vs 12.9%, p = 0.74) as well as improved survival-to-discharge (97.2% vs 91.9%, p = 0.66) was observed. Compared to USAT, standard CDT achieves similar beneficial effects on hemodynamics, RV/LV ratios, and clinical outcomes. These observations suggest that salutary clinical results may be achieved without the need for very expensive devices.
- 14 December 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (3) , 506-510
Low‐dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks
Objectives: The purpose of the present study is to evaluate the safety and efficacy of “low‐dose” systemic thrombolytic therapy (TT) for treatment of patients with intermediate‐high risk submassive pulmonary embolism (PE).Background: TT is increasingly utilized in acute submassive PE. Strategies for TT include catheter‐directed administration as well as traditional IV systemic therapy. Regardless of the route, most studies document the attendant significant bleeding complication rates expected from induction of a systemic lytic state. To mitigate bleeding, “low‐dose” systemic TT (Alteplase 50 mg) has been advocated, based on recent studies which demonstrated clinical efficacy with elimination of any significant bleeding complications.Methods: Over a 24‐month period, our institutional PE Response Team treated 45 acute submassive PE patients with “Low Dose” IV Alteplase 50 mg. Clinical outcomes and bleeding complications were assessed.Results: Overall clinical outcome was excellent, with 97.8% of patients surviving to discharge and a 30‐day, all‐cause mortality of 4.4%. Despite no patients having a HAS‐BLED score > 2 (average score = 0.8 +/−), ISTH major and GUSTO moderate bleeding was observed in 11% (n = 5) of cases.Conclusions: The present observations document that low‐dose systemic TT is associated with excellent clinical outcome for intermediate‐high risk submassive PE, but with attendant risk for bleeding. These findings are consistent with the concept that induction of a therapeutic lytic state carries inextricable bleeding risk.
- 14 December 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 93 (3) , 506-510
Low‐dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks
Objectives: The purpose of the present study is to evaluate the safety and efficacy of “low‐dose” systemic thrombolytic therapy (TT) for treatment of patients with intermediate‐high risk submassive pulmonary embolism (PE).Background: TT is increasingly utilized in acute submassive PE. Strategies for TT include catheter‐directed administration as well as traditional IV systemic therapy. Regardless of the route, most studies document the attendant significant bleeding complication rates expected from induction of a systemic lytic state. To mitigate bleeding, “low‐dose” systemic TT (Alteplase 50 mg) has been advocated, based on recent studies which demonstrated clinical efficacy with elimination of any significant bleeding complications.Methods: Over a 24‐month period, our institutional PE Response Team treated 45 acute submassive PE patients with “Low Dose” IV Alteplase 50 mg. Clinical outcomes and bleeding complications were assessed.Results: Overall clinical outcome was excellent, with 97.8% of patients surviving to discharge and a 30‐day, all‐cause mortality of 4.4%. Despite no patients having a HAS‐BLED score > 2 (average score = 0.8 +/−), ISTH major and GUSTO moderate bleeding was observed in 11% (n = 5) of cases.Conclusions: The present observations document that low‐dose systemic TT is associated with excellent clinical outcome for intermediate‐high risk submassive PE, but with attendant risk for bleeding. These findings are consistent with the concept that induction of a therapeutic lytic state carries inextricable bleeding risk.
- 1 August 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (2) , 372-373
Submassive pulmonary embolus: The challenge of thrombolytic decision‐making in a heterogenous cohort
Key Points: Submassive PE constitutes a heterogenous hemodynamic spectrum Escalation‐of‐care to thrombolytic therapy may benefit some patients suffering submassive PE Comprehensive clinical‐hemodynamic analysis to sub‐stratify submassive PE is essential for thrombolytic decision‐making
- 1 August 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (2) , 372-373
Submassive pulmonary embolus: The challenge of thrombolytic decision‐making in a heterogenous cohort
Key Points: Submassive PE constitutes a heterogenous hemodynamic spectrum Escalation‐of‐care to thrombolytic therapy may benefit some patients suffering submassive PE Comprehensive clinical‐hemodynamic analysis to sub‐stratify submassive PE is essential for thrombolytic decision‐making
- 6 July 2017
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 49 (3) , 281-287
Pacemaker-induced tricuspid regurgitation is uncommon immediately post-implantation
Prior studies report permanent pacemaker (PPM)-induced tricuspid regurgitation (TR) in up to one third of cases late post-implantation. We sought to assess the extent of immediate PPM-induced TR.
- 6 July 2017
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 49 (3) , 281-287
Pacemaker-induced tricuspid regurgitation is uncommon immediately post-implantation
Prior studies report permanent pacemaker (PPM)-induced tricuspid regurgitation (TR) in up to one third of cases late post-implantation. We sought to assess the extent of immediate PPM-induced TR.
- 1 March 2017
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 15 (3) , 77-79
A case of reverse takotsubo cardiomyopathy caused by an eating disorder
- 1 March 2017
- Published by Elsevier in Journal of Cardiology Cases
- Vol. 15 (3) , 77-79
A case of reverse takotsubo cardiomyopathy caused by an eating disorder
- 26 December 2016
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 65 (2) , 445-446
Response to Letter to the Editor: Aging and Statins
- 26 December 2016
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 65 (2) , 445-446
Response to Letter to the Editor: Aging and Statins
- 13 June 2016
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 64 (7) , 1475-1479
Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity‐Adjusted Analysis
Objectives: To examine the effect of statins on long‐term mortality in older adults hospitalized with coronary artery disease ( CAD ). Design: Retrospective analysis. Setting: University teaching hospital. Participants: Individuals aged 80 and older (mean aged 85.2, 56% female) hospitalized from January 2006 to December 2010 with acute myocardial infarction ( AMI ), unstable angina pectoris, or chronic CAD and discharged alive (N = 1,262). Participants were divided into those who did (n = 913) and did not (n = 349) receive a discharge prescription for a statin. Measurements: All‐cause mortality over a median follow‐up of 3.1 years. Results: Participants treated with statins were more likely to be male, to have a primary diagnosis of AMI , to have traditional cardiovascular risk factors, and to receive other standard cardiovascular medications in addition to statins. In unadjusted analysis, statin therapy was associated with lower mortality (hazard ratio ( HR ) = 0.83, 95% confidence interval ( CI ) = 0.71–0.96). After adjustment for baseline differences between groups and propensity for receiving statin therapy, the effect of statins on mortality was no longer significant ( HR = 0.88, 95% CI = 0.74–1.05). The association between statins and mortality was similar in participants aged 80 to 84 and those aged 85 and older. Conclusion: In this cohort of older adults hospitalized with CAD , statin therapy had no significant effect on long‐term survival after adjustment for between‐group differences. These findings, although preliminary, call into question the benefit of statin therapy for secondary prevention in a real‐world population of adults aged 80 and older and underscore the need for shared decision‐making when prescribing statins in this age group.
- 13 June 2016
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 64 (7) , 1475-1479
Effect of Statin Therapy on Mortality in Older Adults Hospitalized with Coronary Artery Disease: A Propensity‐Adjusted Analysis
Objectives: To examine the effect of statins on long‐term mortality in older adults hospitalized with coronary artery disease ( CAD ). Design: Retrospective analysis. Setting: University teaching hospital. Participants: Individuals aged 80 and older (mean aged 85.2, 56% female) hospitalized from January 2006 to December 2010 with acute myocardial infarction ( AMI ), unstable angina pectoris, or chronic CAD and discharged alive (N = 1,262). Participants were divided into those who did (n = 913) and did not (n = 349) receive a discharge prescription for a statin. Measurements: All‐cause mortality over a median follow‐up of 3.1 years. Results: Participants treated with statins were more likely to be male, to have a primary diagnosis of AMI , to have traditional cardiovascular risk factors, and to receive other standard cardiovascular medications in addition to statins. In unadjusted analysis, statin therapy was associated with lower mortality (hazard ratio ( HR ) = 0.83, 95% confidence interval ( CI ) = 0.71–0.96). After adjustment for baseline differences between groups and propensity for receiving statin therapy, the effect of statins on mortality was no longer significant ( HR = 0.88, 95% CI = 0.74–1.05). The association between statins and mortality was similar in participants aged 80 to 84 and those aged 85 and older. Conclusion: In this cohort of older adults hospitalized with CAD , statin therapy had no significant effect on long‐term survival after adjustment for between‐group differences. These findings, although preliminary, call into question the benefit of statin therapy for secondary prevention in a real‐world population of adults aged 80 and older and underscore the need for shared decision‐making when prescribing statins in this age group.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 119
Impact of statin therapy on PSA kinetics during active surveillance of prostate cancer.
119 Background: Statin therapy has been associated with decreased serum PSA levels in men undergoing prostate cancer screening, lower rate of adverse pathologic features in radical prostatectomy specimens and decreased risk of biochemical recurrence following prostatectomy. Here we evaluate the impact of statin therapy on PSA kinetics during active surveillance of prostate cancer. Methods: A retrospective review of patients diagnosed with prostate cancer at our institution between the years 2000 and 2009 was performed. Patients undergoing at least 12 months of active surveillance were identified. PSA velocity and percentage change in PSA per year were compared between patients receiving and not receiving statin therapy during active surveillance. Subgroup analysis was performed on low risk patients (prebiopsy PSA Results: We identified 81 patients meeting our inclusion criteria, 43% (35/81) were on statin therapy during active surveillance. Prebiopsy PSA was significantly lower in patients receiving statin therapy (6.0 ng/ml) compared to controls (8.3 ng/ml), p = 0.005. There was no difference in duration of active surveillance, PSA velocity, and percentage change in PSA per year based on statin use in all patients. When evaluating the 41 low risk patients, 54% (22/41) were on statin therapy. Prebiopsy PSA was lower in low risk patients receiving statin therapy (4.9 ng/ml) compared to controls (6.4 ng/ml), p= 0.055. PSA velocity was significantly lower in low risk patients (0.02 ng/ml/year) compared to low risk controls (0.89 ng/ml/year), p=0.024. Percentage change in PSA per year was significantly lower in low risk patients receiving statin therapy (-1.7%/year) compared to low risk controls (11.6%/year), p=0.05. The percentage of low risk patients receiving definitive therapy following a period of active surveillance on statin therapy was 9% (2/22)compared to 26% (5/19) in controls, p = 0.14. Conclusions: PSA kinetics during active surveillance appear to be significantly altered by statin therapy in low risk patients. Further evaluation of the impact of statin therapy on PSA kinetics and clinical outcomes of men undergoing active surveillance for prostate cancer are warranted.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 119
Impact of statin therapy on PSA kinetics during active surveillance of prostate cancer.
119 Background: Statin therapy has been associated with decreased serum PSA levels in men undergoing prostate cancer screening, lower rate of adverse pathologic features in radical prostatectomy specimens and decreased risk of biochemical recurrence following prostatectomy. Here we evaluate the impact of statin therapy on PSA kinetics during active surveillance of prostate cancer. Methods: A retrospective review of patients diagnosed with prostate cancer at our institution between the years 2000 and 2009 was performed. Patients undergoing at least 12 months of active surveillance were identified. PSA velocity and percentage change in PSA per year were compared between patients receiving and not receiving statin therapy during active surveillance. Subgroup analysis was performed on low risk patients (prebiopsy PSA Results: We identified 81 patients meeting our inclusion criteria, 43% (35/81) were on statin therapy during active surveillance. Prebiopsy PSA was significantly lower in patients receiving statin therapy (6.0 ng/ml) compared to controls (8.3 ng/ml), p = 0.005. There was no difference in duration of active surveillance, PSA velocity, and percentage change in PSA per year based on statin use in all patients. When evaluating the 41 low risk patients, 54% (22/41) were on statin therapy. Prebiopsy PSA was lower in low risk patients receiving statin therapy (4.9 ng/ml) compared to controls (6.4 ng/ml), p= 0.055. PSA velocity was significantly lower in low risk patients (0.02 ng/ml/year) compared to low risk controls (0.89 ng/ml/year), p=0.024. Percentage change in PSA per year was significantly lower in low risk patients receiving statin therapy (-1.7%/year) compared to low risk controls (11.6%/year), p=0.05. The percentage of low risk patients receiving definitive therapy following a period of active surveillance on statin therapy was 9% (2/22)compared to 26% (5/19) in controls, p = 0.14. Conclusions: PSA kinetics during active surveillance appear to be significantly altered by statin therapy in low risk patients. Further evaluation of the impact of statin therapy on PSA kinetics and clinical outcomes of men undergoing active surveillance for prostate cancer are warranted.